Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit ReviewCGS 19755 is a potent, competitive NMDA receptor antagonist. Anticonvulsant and neuroprotective.
分子量 | 223.17 |
公式 | C7H14NO5P |
储存 | Store at RT |
CAS Number | 110347-85-8 |
PubChem ID | 6604838 |
InChI Key | LPMRCCNDNGONCD-NTSWFWBYSA-N |
Smiles | O=P(C[C@@H]1C[C@H]([C@](O)=O)NCC1)(O)O |
上方提供的技术数据仅供参考。批次相关数据请参见分析证书。
Tocris products are intended for laboratory research use only, unless stated otherwise.
溶剂 | 最高浓度 mg/mL | 最高浓度 mM | |
---|---|---|---|
溶解性 | |||
water | 5.58 | 25 |
以下数据基于产品分子量 223.17。 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
浓度/溶剂体积/质量 | 1 mg | 5 mg | 10 mg |
---|---|---|---|
0.25 mM | 17.92 mL | 89.62 mL | 179.24 mL |
1.25 mM | 3.58 mL | 17.92 mL | 35.85 mL |
2.5 mM | 1.79 mL | 8.96 mL | 17.92 mL |
12.5 mM | 0.36 mL | 1.79 mL | 3.58 mL |
参考文献是支持产品生物活性的出版物。
Bennett et al (1989) Behavioral pharmacological profile of CGS 19755, a competitive antagonist at N-MthD.-aspartate receptors. J.Pharmacol.Exp.Ther. 250 454 PMID: 2547931
Lehmann et al (1988) CGS 19755, a selective and competitive N-MthD.-aspartate-type excitatory amino acid receptor antagonist. J.Pharmacol.Exp.Ther. 246 65 PMID: 2899170
Perez-Pinzon et al (1995) Correlation of CGS 19755 neuroprotection against in vivo excitotoxicity and focal cerebral ischemia. J.Cereb.Blood Flow Metab. 15 865 PMID: 7673380
If you know of a relevant reference for CGS 19755, please let us know.
关键词: CGS 19755, CGS 19755 supplier, Potent, competitive, NMDA, antagonists, Glutamate, Receptors, N-Methyl-D-Aspartate, iGlur, Ionotropic, CGS19755, 1241, Tocris Bioscience
引用文献是使用了 Tocris 产品的出版物。 CGS 19755 的部分引用包括:
Pedrazzi et al (2012) Potentiation of NMDA receptor-dependent cell responses by extracellular high mobility group box 1 protein. PLoS One 7 e44518 PMID: 22952988
Jaekel et al (2006) Neuroprotection associated with alternative splicing of NMDA receptors in rat cortical neurons. J Clin Invest 147 622 PMID: 16314856
Pan et al (2014) Deranged NMDAergic cortico-subthalamic transmission underlies parkinsonian motor deficits. J Pharmacol Exp Ther 124 4629 PMID: 25202982
Richardson and Shelton (2015) N-MthD.-aspartate receptor channel blocker-like discriminative stimulus effects of nitrous oxide gas. Cereb Cortex 352 156 PMID: 25368340
您是否知道使用了 Tocris CGS 19755 的优秀论文? 请告知我们.
目前没有该产品的评论。 Be the first to review CGS 19755 and earn rewards!
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*请注意,Tocris 仅会向正规科研企业/机构地址发送文献。
This product guide provides a background to Huntington's disease research and lists around 100 products for the study of:
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Huntington's disease (HD) is a severe monogenic neurodegenerative disorder, which is characterized by the prevalent loss of GABAergic medium spiny neurons (MSN) in the striatum. This poster summarizes the effects of mutant huntingtin aggregation implicated in the pathology of HD, as well as highlighting the use of iPSCs for HD modeling.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.